Oxaborole Antifungal [EPC]

Oxaborole Antifungal [EPC] was reported 70 times

These side effects are most commonly reported by patients taking drugs of the Oxaborole Antifungal [EPC] class:

# Drug class Count
0 DRUG INEFFECTIVE 11
1 OFF LABEL USE 6
2 INJECTION SITE PAIN 4
3 PRODUCT DOSE OMISSION IN ERROR 4
4 PRODUCT PACKAGING QUANTITY ISSUE 4
5 PRURITUS 4
6 COUGH 3
7 DIARRHOEA 3
8 PERIPHERAL SWELLING 3
9 RASH 3
10 SKIN IRRITATION 3
11 ACCIDENTAL EXPOSURE TO PRODUCT 2
12 ALOPECIA 2
13 APPLICATION SITE DRYNESS 2
14 ASTHMA 2
15 BACK INJURY 2
16 DEATH 2
17 DERMATITIS ATOPIC 2
18 DYSPNOEA 2
19 FATIGUE 2
20 HEADACHE 2
21 HYPERSENSITIVITY 2
22 ILLNESS 2
23 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 2
24 INFECTION 2
25 INFLUENZA 2
26 MALAISE 2
27 NASOPHARYNGITIS 2
28 NO ADVERSE EVENT 2
29 ONYCHOCLASIS 2
30 PAIN IN EXTREMITY 2
31 PRODUCT CONTAINER ISSUE 2
32 PRODUCT CONTAINER SEAL ISSUE 2
33 PRODUCT USE IN UNAPPROVED INDICATION 2
34 SKIN EXFOLIATION 2
35 WEIGHT DECREASED 2
36 ABDOMINAL DISCOMFORT 1
37 ADVERSE EVENT 1
38 ALANINE AMINOTRANSFERASE INCREASED 1
39 APPETITE DISORDER 1
40 APPLICATION SITE ERYTHEMA 1
41 APPLICATION SITE EXFOLIATION 1
42 APPLICATION SITE HYPOAESTHESIA 1
43 APPLICATION SITE IRRITATION 1
44 APPLICATION SITE SWELLING 1
45 ARTHRALGIA 1
46 ARTHRITIS 1
47 ATRIAL FIBRILLATION 1
48 BLINDNESS 1
49 BLISTER 1
50 BLOOD POTASSIUM DECREASED 1
51 BLOOD PRESSURE INCREASED 1
52 BODY DYSMORPHIC DISORDER 1
53 CHEMICAL BURN 1
54 CHILLS 1
55 CHOLELITHIASIS 1
56 COVID-19 1
57 CYSTITIS 1
58 DEAFNESS 1
59 DERMATITIS ALLERGIC 1
60 DEVICE DELIVERY SYSTEM ISSUE 1
61 DRUG HYPERSENSITIVITY 1
62 DRY SKIN 1
63 DYSPEPSIA 1
64 DYSPHONIA 1
65 EAR OPERATION 1
66 ECZEMA 1
67 EXPOSURE VIA SKIN CONTACT 1
68 EYE PRURITUS 1
69 FAECES SOFT 1
70 FALL 1
71 FAT TISSUE INCREASED 1
72 FLATULENCE 1
73 FUNGAL FOOT INFECTION 1
74 FUNGAL SKIN INFECTION 1
75 GAIT DISTURBANCE 1
76 GASTROENTERITIS VIRAL 1
77 GASTROINTESTINAL SOUNDS ABNORMAL 1
78 GASTROOESOPHAGEAL REFLUX DISEASE 1
79 GLYCOSYLATED HAEMOGLOBIN INCREASED 1
80 HEART RATE INCREASED 1
81 HOSPITALISATION 1
82 HYPERAMMONAEMIA 1
83 HYPERHIDROSIS 1
84 IMMUNISATION REACTION 1
85 INCORRECT DOSE ADMINISTERED 1
86 INCORRECT DRUG ADMINISTRATION RATE 1
87 INFUSION RELATED REACTION 1
88 INFUSION SITE BRUISING 1
89 INFUSION SITE DISCOMFORT 1
90 INFUSION SITE INFLAMMATION 1
91 INGROWING NAIL 1
92 INJECTION SITE DISCOMFORT 1
93 INJECTION SITE ERYTHEMA 1
94 INJECTION SITE HAEMORRHAGE 1
95 INJECTION SITE IRRITATION 1
96 INJECTION SITE SWELLING 1
97 INJECTION SITE WARMTH 1
98 INTENTIONAL DOSE OMISSION 1
99 INTENTIONAL PRODUCT MISUSE 1
100 JOINT INJURY 1
101 JOINT SWELLING 1
102 LACRIMATION INCREASED 1
103 LIMB INJURY 1
104 LIQUID PRODUCT PHYSICAL ISSUE 1
105 MOUTH ULCERATION 1
106 MUSCLE SPASMS 1
107 MUSCULOSKELETAL STIFFNESS 1
108 NAIL DISORDER 1
109 NAIL GROWTH ABNORMAL 1
110 NAUSEA 1
111 ONYCHOMALACIA 1
112 ONYCHOMYCOSIS 1
113 PAIN 1
114 PAIN OF SKIN 1
115 PANCREATIC CYST 1
116 PRIMARY STABBING HEADACHE 1
117 PRODUCT ADMINISTERED AT INAPPROPRIATE SITE 1
118 PRODUCT DELIVERY MECHANISM ISSUE 1
119 PRODUCT DOSE OMISSION ISSUE 1
120 PRODUCT INEFFECTIVE FOR UNAPPROVED USE 1
121 PRODUCT LEAKAGE 1
122 PRODUCT OUTER PACKAGING ISSUE 1
123 PRODUCT PACKAGE ASSOCIATED INJURY 1
124 PRODUCT QUALITY ISSUE 1
125 PRODUCT USE COMPLAINT 1
126 PYELONEPHRITIS 1
127 RIB DEFORMITY 1
128 SEIZURE 1
129 SHORT-BOWEL SYNDROME 1
130 SINUSITIS 1
131 SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION 1
132 SNORING 1
133 SURGERY 1
134 TACHYPNOEA 1
135 TEMPOROMANDIBULAR PAIN AND DYSFUNCTION SYNDROME 1
136 THERAPEUTIC RESPONSE DECREASED 1
137 THERAPY CESSATION 1
138 THERAPY PARTIAL RESPONDER 1
139 THROMBOSIS 1
140 THYROID CANCER 1
141 THYROID DISORDER 1
142 TRANSIENT ISCHAEMIC ATTACK 1
143 URINARY TRACT INFECTION 1
144 VASCULAR DEVICE INFECTION 1
145 VISUAL IMPAIRMENT 1
146 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 1